Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Schellhammer

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
The Journal of Urology|December 3, 2014
The clinical and economic implications of specimen provenance complications in diagnostic prostate biopsiesKirk Wojno, John Hornberger, Paul Schellhammer, et al.
The Canadian Journal of Urology|February 17, 2010
Feasibility of using guidelines to choose treatment for prostate cancerRavinder Mohan, Hind Beydoun, John Davis, et al.
BJU International|February 16, 2010
Development of a scale to assess patient misperceptions about treatment choices for localized prostate cancerHind A Beydoun, Ravinder Mohan, May A Beydoun, et al.
International Journal of Radiation Oncology, Biology, Physics|June 27, 2006
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceMack Roach, Gerald Hanks, Howard Thames, et al.
Nature Reviews. Drug Discovery|July 2, 2010
Sipuleucel-TCelestia S Higano, Eric J Small, Paul Schellhammer, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 7, 2010
Self-rated health as a tool for estimating health-adjusted life expectancy among patients newly diagnosed with localized prostate cancer: a preliminary studyRavinder Mohan, Hind A Beydoun, May A Beydoun, et al.
Journal of the American Board of Family Medicine : JABFM|May 12, 2009
Patients' survival expectations before localized prostate cancer treatment by treatment statusRavinder Mohan, Hind Beydoun, Myra L Barnes-Ely, et al.
BJU International|October 28, 2010
5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic reviewTimothy J Wilt, Roderick Macdonald, Karen Hagerty, et al.
The Journal of Urology|March 15, 2013
Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processingMarc A Bjurlin, H Ballentine Carter, Paul Schellhammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugsJune M McKoy, E Allison Lyons, Eniola Obadina, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
The Journal of Urology|December 3, 2014
The clinical and economic implications of specimen provenance complications in diagnostic prostate biopsiesKirk Wojno, John Hornberger, Paul Schellhammer, et al.
The Canadian Journal of Urology|February 17, 2010
Feasibility of using guidelines to choose treatment for prostate cancerRavinder Mohan, Hind Beydoun, John Davis, et al.
BJU International|February 16, 2010
Development of a scale to assess patient misperceptions about treatment choices for localized prostate cancerHind A Beydoun, Ravinder Mohan, May A Beydoun, et al.
International Journal of Radiation Oncology, Biology, Physics|June 27, 2006
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceMack Roach, Gerald Hanks, Howard Thames, et al.
Nature Reviews. Drug Discovery|July 2, 2010
Sipuleucel-TCelestia S Higano, Eric J Small, Paul Schellhammer, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 7, 2010
Self-rated health as a tool for estimating health-adjusted life expectancy among patients newly diagnosed with localized prostate cancer: a preliminary studyRavinder Mohan, Hind A Beydoun, May A Beydoun, et al.
Journal of the American Board of Family Medicine : JABFM|May 12, 2009
Patients' survival expectations before localized prostate cancer treatment by treatment statusRavinder Mohan, Hind Beydoun, Myra L Barnes-Ely, et al.
BJU International|October 28, 2010
5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic reviewTimothy J Wilt, Roderick Macdonald, Karen Hagerty, et al.
The Journal of Urology|March 15, 2013
Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processingMarc A Bjurlin, H Ballentine Carter, Paul Schellhammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugsJune M McKoy, E Allison Lyons, Eniola Obadina, et al.
Pageof 3